VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 2003

Primary Completion Date

September 30, 2004

Study Completion Date

January 31, 2008

Conditions
LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

cytarabine

DRUG

laromustine

Trial Locations (1)

77030-4095

University of Texas - MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Vion Pharmaceuticals

INDUSTRY

NCT00070538 - VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies | Biotech Hunter | Biotech Hunter